As the push continues to create a vaccination for COVID-19, Morehouse School of Medicine (MSM) is conducting two novel coronavirus-related clinical trials.
As MSM’s clinical trials are happening locally, Pfizer and Moderna recently announced promising results from their Phase 3 trials. According to Pfizer, their vaccine appears to be more than 90% effective and Moderna’s vaccine appears to be 94.5% effective.
Lilly Immergluck, an associate professor of microbiology, biochemistry, immunology and pediatrics and the director of the Pediatric Clinical & Translational Research Unit, Clinical Research Center, joined Monday’s edition of “Closer Look.”
Read this story and all our reporting for free — forever.
Sign up for our newsletter to support WABE’s mission of delivering independent, in-depth journalism — and hand-picked NPR stories that matter to Atlanta.
We will never share your email address with others. How does your newsletter sign-up support WABE and Public Media...
